Kezar Life Sciences, Inc. (KZR)

NASDAQ: KZR · Real-Time Price · USD
0.774
-0.024 (-2.95%)
At close: Oct 7, 2024, 4:00 PM
0.800
+0.026 (3.36%)
After-hours: Oct 7, 2024, 7:41 PM EDT
-2.95%
Market Cap 56.47M
Revenue (ttm) 7.00M
Net Income (ttm) -98.57M
Shares Out 72.96M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 569,531
Open 0.770
Previous Close 0.798
Day's Range 0.743 - 0.783
52-Week Range 0.520 - 1.140
Beta 0.21
Analysts Hold
Price Target 2.00 (+158.4%)
Earnings Date Nov 11, 2024

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 58
Stock Exchange NASDAQ
Ticker Symbol KZR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for KZR stock is "Hold." The 12-month stock price forecast is $2.0, which is an increase of 158.40% from the latest price.

Price Target
$2.0
(158.40% upside)
Analyst Consensus: Hold
Stock Forecasts

News

US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial

The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' trial of experimental drug for lupus, the company said on Friday.

3 days ago - Reuters

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated ...

3 days ago - Business Wire

Kezar Life Sciences halts mid-stage trial for lupus treatment

Kezar Life Sciences said on Monday it was stopping enrollment of new patients and dosing of ongoing patients in its mid-stage study for treating a symptom of lupus, following the recommendation of an ...

7 days ago - Reuters

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated ...

7 days ago - Business Wire

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

4 weeks ago - Business Wire

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

7 weeks ago - Business Wire

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

3 months ago - Business Wire

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

4 months ago - Business Wire

Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

5 months ago - Business Wire

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

5 months ago - Business Wire

Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disor...

7 months ago - Business Wire

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disor...

7 months ago - Business Wire

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

SHANGHAI & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China...

8 months ago - Business Wire

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disor...

11 months ago - Business Wire

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update.

11 months ago - Business Wire

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disor...

1 year ago - Business Wire

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big phar...

Other symbols: BGNEBMYNVSOCUL
1 year ago - Seeking Alpha

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $KZR--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune med...

1 year ago - Business Wire

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $KZR--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-med...

1 year ago - Business Wire

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: ALLKBLFSTCRT
1 year ago - Benzinga

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $KZR--Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update.

1 year ago - Business Wire

Kezar Life Sciences to Participate in the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and...

1 year ago - Business Wire

Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and...

1 year ago - Business Wire

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and...

1 year ago - Business Wire

Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and...

1 year ago - Business Wire